ClinicalTrials.gg
CompletedNCT00090363Updated Jan 8, 2013Results posted

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

A Phase 2 interventional study of ZD4054 15 mg and Placebo in Prostate Cancer, sponsored by AstraZeneca. Completed at 60 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-08.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
447
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Enrollment
16th of 60
447 · median 110
Started
2004
with 2 others
Phase 2
16 of 91
none open now
Registered
4th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 16th largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2004, is one of 16 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

This study is being carried out to see if ZD4054 (Zibotentan) is effective in treating prostate cancer and spread of cancer to the bone, and if so, how it compares with placebo (sugar pill). The study will also provide further information on the safety of ZD4054 (Zibotentan).

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • rising PSA
  • bone metastases
  • Clinical study
  • pain-free or mildly symptomatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgically or medically castrated
  • Bone
  • Rising PSA

Exclusion criteria

Exclusion Criteria:

  • Opiate use
  • Prior chemotherapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
447 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo oral tablet once daily, with best supportive care

    Drug: Placebo

  • Experimental
    ZD4054 10 mg

    ZD4054 10 mg oral tablet once daily, with best supportive care

    Drug: ZD4054 10 mg

  • Experimental
    ZD4054 15 mg

    ZD4054 15 mg oral tablet once daily, with best supportive care

    Drug: ZD4054 15 mg

Interventions

  • 15 mg oral tablet once daily

    Also known as: Zibotentan

  • DrugPlacebo
  • 10mg oral tablet once daily

    Also known as: (Zibotentan)

06

What researchers measure

Primary outcomes

  1. Time to Progression (TTP)

    Median time (in days) from randomisation until disease progression, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline or death using the Kaplan-Meier method.

    Time frame: Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008).

Secondary outcomes

  1. Time to Death

    Median time (in days) from randomisation until death using the Kaplan-Meier method.

    Time frame: Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. After progression survival was assessed 6-monthly. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008).

  2. Change in Total Prostate Specific Antigen (PSA) Over Time

    Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to 12 weeks.

    Time frame: Baseline to 12 weeks. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006).

  3. Objective Response Rate (ORR)

    Using the Response Evaluation Criteria in Solid Tumours (RECIST), an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR), which is subsequently confirmed as per RECIST. Objective Response Rate (ORR) is defined as the percentage of patients with OR.

    Time frame: For patients with measurable disease at baseline, Response Evaluation Criteria in Solid Tumours (RECIST) scans were 12-weekly from randomisation. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006).

  4. Change in Number of Bone Metastases Over Time

    Percentage change in the number of bone metastases from baseline to last available post-baseline scan prior to discontinuation.

    Time frame: Baseline to last available post-baseline scan prior to discontinuation, up to maximum of 1164 days.

07

Results

Posted Sep 3, 2012
Limitations and caveats
'Final analysis' results (data cut-off 18th December 2008) should be considered in context with the longevity of the follow-up (median duration approximately 22 months) relative to only approximately 4 months median duration of study treatment.

Participant flow

447 patients with prostate cancer who had bone metastases with no pain or mild symptoms of pain and a rising serum Prostate Specific Antigen (PSA), despite a serum testosterone of \<= 2.4 nmol/L (70 ng/dL), were recruited between 14th July 2004 and 10th January 2006.

Participant flow — Overall Study
MilestonePlaceboZD4054 10 mgZD4054 15 mg
Started10710798
Received study treatment.10710798
Completed102
Not completed10610796
Withdrew: Lost to follow-up121
Withdrew: Withdrawal by subject776
Withdrew: Study-specific discontinuation criteria757462
Withdrew: Eligibility criteria not fulfilled001
Withdrew: Consent expired7109
Withdrew: Reasons not specified211
Withdrew: Continuing on study off treatment141316

Outcome measures

PrimaryTime to Progression (TTP)

Median time (in days) from randomisation until disease progression, where progression is defined, using RECIST, as a measurable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline or death using the Kaplan-Meier method.

Time frame:
Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008).
Reported as:
Median · Days
Time to Progression (TTP)
DaysPlaceboZD4054 10 mgZD4054 15 mg
Time to Progression (TTP)111 (77 to 252)138 (80 to 247)113 (80 to 279)
SecondaryTime to Death

Median time (in days) from randomisation until death using the Kaplan-Meier method.

Time frame:
Follow-up for progression/death was 4-weekly for 2 years after first dose and 3-monthly thereafter. After progression survival was assessed 6-monthly. 'Final analysis' results are given - the most recent formal analysis (data cut-off 18th December 2008).
Reported as:
Median · Days
Time to Death
DaysPlaceboZD4054 10 mgZD4054 15 mg
Time to Death596 (317 to 893)706 (457 to 1043)717 (452 to 1232)
SecondaryChange in Total Prostate Specific Antigen (PSA) Over Time

Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to 12 weeks.

Time frame:
Baseline to 12 weeks. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006).
Reported as:
Mean · Percentage Change in PSA
Change in Total Prostate Specific Antigen (PSA) Over Time
Percentage Change in PSAPlaceboZD4054 10 mgZD4054 15 mg
Change in Total Prostate Specific Antigen (PSA) Over Time110.4 ± 179.16131.6 ± 454.3569.34 ± 99.14
SecondaryObjective Response Rate (ORR)

Using the Response Evaluation Criteria in Solid Tumours (RECIST), an objective response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR), which is subsequently confirmed as per RECIST. Objective Response Rate (ORR) is defined as the percentage of patients with OR.

Time frame:
For patients with measurable disease at baseline, Response Evaluation Criteria in Solid Tumours (RECIST) scans were 12-weekly from randomisation. 'Initial analysis' results are given - the most recent formal analysis (data cut-off 10th April 2006).
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsPlaceboZD4054 10 mgZD4054 15 mg
Objective Response Rate (ORR)000
SecondaryChange in Number of Bone Metastases Over Time

Percentage change in the number of bone metastases from baseline to last available post-baseline scan prior to discontinuation.

Time frame:
Baseline to last available post-baseline scan prior to discontinuation, up to maximum of 1164 days.
Reported as:
Mean · Percentage Change
Change in Number of Bone Metastases Over Time
Percentage ChangePlaceboZD4054 10 mgZD4054 15 mg
Change in Number of Bone Metastases Over Time187.1 ± 212.6113.4 ± 195.6189 ± 245.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—26/107 (24.3%)93/107 (86.9%)
ZD4054 10 mg—18/107 (16.8%)86/107 (80.4%)
ZD4054 15 mg—16/98 (16.3%)87/98 (88.8%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPlaceboZD4054 10 mgZD4054 15 mg
AnaemiaBlood and lymphatic system disorders2/1073/1071/98
Cardiac FailureCardiac disorders0/1073/1070/98
Myocardial InfarctionCardiac disorders0/1071/1072/98
HaematuriaRenal and urinary disorders0/1071/1072/98
Cardiopulmonary FailureCardiac disorders0/1072/1070/98
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1070/1070/98
VomitingGastrointestinal disorders1/1070/1071/98
Abdominal Pain UpperGastrointestinal disorders0/1070/1071/98
ConstipationGastrointestinal disorders0/1070/1071/98
Gastric Ulcer HaemorrhageGastrointestinal disorders0/1070/1071/98
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlaceboZD4054 10 mgZD4054 15 mg
Oedema PeripheralGeneral disorders47/10742/10711/98
HeadacheNervous system disorders44/10739/10713/98
Nasal CongestionRespiratory, thoracic and mediastinal disorders34/10731/1074/98
NauseaGastrointestinal disorders13/10719/10720/98
ConstipationGastrointestinal disorders11/10713/10718/98
Back PainMusculoskeletal and connective tissue disorders19/10718/10717/98
FatigueGeneral disorders7/10718/10710/98
DyspnoeaRespiratory, thoracic and mediastinal disorders6/10717/1076/98
Rhinitis AllergicRespiratory, thoracic and mediastinal disorders15/10717/1073/98
Pain In ExtremityMusculoskeletal and connective tissue disorders7/10710/10712/98

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboZD4054 10 mgZD4054 15 mgTotal
Mean71 ± 970 ± 869 ± 870 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboZD4054 10 mgZD4054 15 mgTotal
Female0000
Male10710798312
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboZD4054 10 mgZD4054 15 mgTotal
Caucasian10610793306
Black0011
Oriental1034
Other0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboZD4054 10 mgZD4054 15 mgTotal
Hispanic34310
African-American0011
Asian1034
Japanese0011
Not a specific ethnic group999587281
Other48315
08

Study locations

60 sites
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Gainsville, Florida, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Simpsonville, South Carolina, United States
  • Research Site
    Wolloongabba, Queensland, Australia
  • Research Site
    Ashford, South Australia, Australia
  • Research Site
    Wodonga, Victoria, Australia
  • Research Site
    Nedlands, Australia
  • Research Site
    Brussels, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Leuven, Belgium
  • Research site
    Vancouver, British Columbia, Canada
  • Research site
    London, Ontario, Canada
  • Research site
    Toronto, Ontario, Canada
  • Research site
    Montreal, Quebec, Canada
  • Research site
    Quebec, Canada
  • Research Site
    Arhus, Denmark
  • Research Site
    Herlev, Denmark
  • Research Site
    Helsinki, Finland
  • Research Site
    Joensuu, Finland
  • Research Site
    OYS, Finland
  • Research Site
    Seinäjoki, Finland
  • Research Site
    Tampere, Finland
  • Research Site
    Lille, France
  • Research Site
    Montpellier, France
  • Research Site
    Paris, France
  • Research site
    Pontoise, France
  • Research Site
    Toulouse, France
  • Research Site
    Jakarta, Indonesia
  • Research Site
    Eindhoven, Netherlands
  • Research Site
    Groningen, Netherlands
  • Research Site
    Heerlen, Netherlands
  • Research Site
    Leiden, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Utrecht, Netherlands
  • Research Site
    Bergen, Norway
  • Research Site
    Fredrikstad, Norway
  • Research Site
    Moelv, Norway
  • Research Site
    Oslo, Norway
  • Research Site
    Tonsberg, Norway
  • Research Site
    Tromso, Norway
  • Research Site
    Trondheim, Norway
  • Research Site
    Bydgoszcz, Poland
  • Research Site
    Katowice, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Goteborg, Sweden
  • Research Site
    Malmo, Sweden
  • Research Site
    Stockholm, Sweden
  • Research Site
    Geneve, Switzerland
  • Research Site
    Locarno, Switzerland
  • Research Site
    Birmingham, United Kingdom
  • Research Site
    Leeds, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Maidstone, United Kingdom
  • Research Site
    Manchester, United Kingdom
  • Research Site
    Newcastle, United Kingdom
  • Research Site
    York, United Kingdom
09

References and documents

Publications

  • James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29. PubMed 19042080 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Dec 2008 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years 9 months after primary completion. A results delay was requested in May 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2004
First posted
Aug 30, 2004
Start
Jul 2004
Primary completionActual
Dec 2008
CompletionActual
Aug 2011
Results delay requested
May 23, 2011
Results first posted
Sep 3, 2012
Last update
Jan 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00090363
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 30, 2004
Start date
Jul 2004
Primary completion
Dec 2008
Completion
Aug 2011
Results posted
Sep 3, 2012
Last update
Jan 8, 2013

Study contacts

AstraZeneca Emerging Oncology Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion